Reducing hair loss from chemotherapy: a new partnership

1 Nov 2014

Researchers in partnership with the industry are analyzing the science required to stop hair loss from chemotherapy and improve cancer patients' quality of life. In particular, a scalp cooling equipment company is funding University research for such devices.

The company is called Paxman Coolers and will fund research at the University of Huddersfield.

CareAcross-smiling-woman

Hair loss an important side effect of chemotherapy

Hair loss that is often an emotionally devastating consequence of chemotherapy can be halted by the use of special scalp cooling devices used before, during and after treatment.

The success of the project means that the company, Huddersfield-based Paxman Coolers, will provide funding so that key researcher Omar Hussain (who has an academic background in the pharmacology of cancer treatment) can continue to work on scalp cooling as he progresses towards his PhD.

Paxman have collaborated with the biology department of the University of Huddersfield on a Government-backed Knowledge Transfer Partnership (KTP), designed to establish the scientific basis of scalp cooling and its success rate with different drugs. Omar was the KTP Associate, supervised by the University's Dr Nik Georgopoulos and Dr Andrew Collett.

International collaboration to support clinical evidence

Now, an article in the specialist journal Toxicology in Vitro reports on the findings of the project. Omar Hussain is a co-author, alongside four University of Huddersfield scientists plus colleagues from a research institute in the Netherlands. They summarize the results of lab tests that provide experimental evidence that cooling can markedly reduce the hair loss caused by some of the drugs most commonly used in chemotherapy. This supports the clinical evidence.

There is also evidence that the choice of temperature can be crucial and the way is paved for further research, which will now be conducted by Omar Hussain, to be based at Paxman and at the University of Huddersfield, where his PhD supervisors will be Dr Collett and Dr Georgopoulos.

Goal: reduce chances of hair loss to 20%

For Richard Paxman, who is managing director of the company that manufactures and markets scalp cooling systems (with 2,000 now in use around the world) the research collaboration with the University of Huddersfield has been a major success that will enable further improvements in the treatment and the technology.

"When a patient comes to us and asks what the chances are of keeping their hair, at the moment we are very fair and say they are 50%. Now we want to take that up to 80% and we believe that greater understanding of the scientific mechanisms will allow us to do that," he said.

Research details

Omar Hussain - who has presented his research at several international conferences, in tandem with a Paxman team - described how he replicated the effect of scalp cooling in laboratory conditions.

Cells were taken from hair follicles and subjected to a simulation of chemotherapy treatment. Experiments were conducted with different levels of temperature, from 37 degrees C (the normal temperature of the human body) and then lowered. As the temperatures fell, cell survival increased.

"Compared with 37 degrees there are huge differences," said Omar. "At low temperatures, cells are being rescued and maintained well and this promotes the cooling effect." He added that the optimum temperature for scalp cooling is yet to be finalized, although it is below 22 degrees C.

How is the scalp cooler used?

A patient wears a scalp cooler for 30 minutes before chemotherapy, continues to wear it during treatment and for 90 minutes afterwards. As part of his research, Omar Hussain tested the response of more than 50 people (Paxman staff plus University staff and students) to wearing the device.

"The first ten minutes are when everybody feels a slight discomfort. After that they are fine," he said.

 

Source: Medical News Today

No Comment